צמיחת מכירות ב-12 חודשים נגררים: Upstream Bio Inc (UPB)

Upstream Bio Inc (UPB) faces geopolitical risks regarding patent protection and is managing capital expenditure during the testing of immunotherapeutic drugs. The GURU.Markets system provides the annual revenue growth trend over a rolling 12-month period, where 2.60 characterizes this valuation parameter. Business development relies on partnerships with laboratories to create medications for allergies and asthma.
Upstream Pharma (UPB) - פילוחי מדדים ודוחות פיננסיים

To minimize fundamental risks, investors should select assets with sustainable revenue expansion, which this metric calculates as the percentage change in total income over the last twelve months relative to the same period last year. In the context of immune drug development, Upstream Bio Inc (UPB) operating revenue growth YoY (TTM) reflects the commercial efficiency of innovations and the success of clinical trials.